U of M Hematology/Oncology Pharmacy

Research

FLAG + Venetoclax for the Treatment of Front Line Secondary AML
7 +3 + Venetoclax for the Treatment of De Novo AML
Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML
Outcomes in AML Patients Receiving 10-day Decitabine with or without Venetoclax Therapy
Comparison of Re-induction Chemotherapy Regimen in AML
Impact of FLT3 inhibitors in FLT3+ AML
High-Dose Cytarabine Dosing in Obese Patients with AML
Creation and Impact of a Multidisciplinary Asparaginase Allergy Review Committee to Manage the Global Erwinia Asparaginase Shortage
Evaluation of thrombosis rates with PEG-asparaginase Therapy Using Prophylactic Cryoprecipitate and Fresh Frozen Plasma
Comparing Late Complications Following R-Bendamustine versus R-CHOP or R-CVP in patients with Follicular Lymphoma
Safety, Efficacy, and Activity Levels in Acute Lymphoblastic Leukemia (ALL) Patients Receiving an Attenuated Dose of PEG-Asparaginase

Evaluation of the Effect of Plerixafor Stem Cell Mobilization on Multiple Myeloma Relapse Rates

Febrile Neutropenia Antibiotic De-escalation Study in Acute Myeloid Leukemia Patients with Prolonged Neutropenia
Impact of Antifungal Agent Used for Prophylaxis Against Invasive Fungal Infections During Induction Therapy for Acute Myeloid Leukemia
Impact of Standard versus Prolonged Courses of Antibiotics for the Treatment of Uncomplicated Staphylococcus aureus Bloodstream Infections in Patients with Hematologic Malignancies
Impact of inhaled versus oral ribavirin on outcomes in high risk oncology patients with respiratory syncytial virus infections
Clinical utility of MRSA nasal screening in heme/onc Patients with febrile neutropenia to rule out MRSA Pneumonia
Does CLABSI risk correlate with number of lumens in central venous catheters?

A Phase 2 Study of Dasatinib in Combination with Everolimus for Children with Gliomas Harboring PDGFR/FGFR Alterations. NCT03352427
A Phase 2 Study of Panobinostat in Combination with Everolimus for Children and Young Adults with Gliomas Harboring H3.3 or H3.1 K27M Mutation

Longer-Interval Vs Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small Cell Lung Cancer and Small Cell Lung Cancer Patients with Bone Metastases
Impact of Integrating Clinical Research Pharmacy Services in the Expanded Access Process in Pediatric Oncology Patients

The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia (June 2018) Published in Leukemia Research in July 2018, the leukemia team at UM has shown that FLAG chemotherapy produced a 70% ORR in sAML with only 3% induction mortality.
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG (April 2018) Published in the Annals of Hematology, Scappaticci and colleagues demonstrated that FLAG reinduction resulted in higher CR/CRi and better OS, with significantly less toxicity and cost.
Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report (January 2018)

Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology (March 2018) Published in the Journal of Neuro-Oncology, the precision medicine team created a formalized algorithm - CNS-TAP - to optimize the selection of targeted therapies with the highest chance for success.

Google Sites

Report abuse